EMA seeks views on its access to data policy
A three-month consultation about releasing clinical trials data which is considered non-commercially sensitive has been launched by the European Medicines Agency.
The draft EMA policy on proactive access to the data will be open for consultation until the end of September 2013. The findings will help shape the EMA’s final strategy, which is due to be published in November.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2013.11122761
Recommended from Pharmaceutical Press